Lavipharm S.A. (FRA:BXA0)

Market Cap	267.10M +97.4%
Revenue (ttm)	64.53M +23.0%
Net Income	5.18M -45.5%
EPS	0.03
Shares Out	n/a
PE Ratio	51.60
Forward PE	n/a
Dividend	0.02 (1.34%)
Ex-Dividend Date	Jul 17, 2025

Volume	n/a
Open	1.470
Previous Close	1.690
Day's Range	1.470 - 1.500
52-Week Range	0.706 - 1.850
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Pharmaceutical Preparations
• Founded: 1911
• Employees: 285
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BXA0

Financial Performance

In 2025, Lavipharm's revenue was 62.58 million, an increase of 18.20% compared to the previous year's 52.95 million. Earnings were 5.99 million, a decrease of -33.36%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error